Publications by authors named "Ted Blanchard"
Impact of Baseline and Week 2 and Week 4 Posttransplant CMV Cell-Mediated Immunity on Risk of CMV Infections and Mortality in Recipients of Allogeneic Hematopoietic Cell Transplant.
Open Forum Infect Dis
August 2023
Article Synopsis
- Cytomegalovirus (CMV) is a common infection that can occur after allogeneic hematopoietic cell transplant (alloHCT), and this study examines how changes in CMV-specific immune responses in the first month post-transplant can predict infection risk and mortality.
- The study analyzed data from 226 alloHCT recipients, identifying key predictors of clinically significant CMV infection (CS-CMVi) such as decreased T-cell response to CMV antigens and factors like transplant type and use of corticosteroids.
- Findings suggest that a decline in CMV-specific immune responses, particularly from week 2 to week 4 after transplant, is linked to a higher risk of CMV infection and increased overall mortality among
Background: Cytomegalovirus (CMV) infection remains an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) recipients. CMV cell-mediated immunity (CMV-CMI) as determined by a peptide-based enzyme-linked immunospot (ELISPOT) CMV assay may identify patients at risk for clinically significant CMV infection (CS-CMVi).
Methods: The CS-CMVi was defined as CMV viremia and/or disease necessitating antiviral therapy.
T cell immunity is essential for the control of cytomegalovirus (CMV) infection after transplantation. We evaluated a CMV-specific peptide-based enzyme-linked immunosorbent spot (ELISPOT) assay to determine whether assay results could predict subsequent CMV events. Adult kidney transplant recipients at 43 centers underwent ELISPOT testing to enumerate interferon gamma (IFN-γ) binding spot-forming units (sfu) after stimulation of cells with an overlapping peptide pool of CMV phosphoprotein 65 (pp65) and immediate early-1 (IE-1) protein at the end of antiviral prophylaxis (EOP) and various time points thereafter.
View Article and Find Full Text PDFBackground: Cytomegalovirus (CMV) infections in hematopoietic cell transplant (HCT) recipients cause substantial morbidity and mortality. CMV cell-mediated immunity (CMV-CMI) can be determined by levels of interferon gamma (IFN-γ) production using an enzyme-linked immunospot (ELISPOT) CMV assay (T-SPOT.CMV assay).
View Article and Find Full Text PDF